BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30737440)

  • 1. Probing the Inhibition of Microtubule Affinity Regulating Kinase 4 by N-Substituted Acridones.
    Voura M; Khan P; Thysiadis S; Katsamakas S; Queen A; Hasan GM; Ali S; Sarli V; Hassan MI
    Sci Rep; 2019 Feb; 9(1):1676. PubMed ID: 30737440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, molecular docking and inhibition studies of novel 3-N-aryl substituted-2-heteroarylchromones targeting microtubule affinity regulating kinase 4 inhibitors.
    Parveen I; Khan P; Ali S; Hassan MI; Ahmed N
    Eur J Med Chem; 2018 Nov; 159():166-177. PubMed ID: 30290280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of human microtubule affinity-regulating kinase 4 inhibitors: fluorescence binding studies, enzyme, and cell assays.
    Naz F; Sami N; Naqvi AT; Islam A; Ahmad F; Imtaiyaz Hassan M
    J Biomol Struct Dyn; 2017 Nov; 35(14):3194-3203. PubMed ID: 27748164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and development of Isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis.
    Aneja B; Khan NS; Khan P; Queen A; Hussain A; Rehman MT; Alajmi MF; El-Seedi HR; Ali S; Hassan MI; Abid M
    Eur J Med Chem; 2019 Feb; 163():840-852. PubMed ID: 30579124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing New Kinase Inhibitor Derivatives as Therapeutics Against Common Complex Diseases: Structural Basis of Microtubule Affinity-Regulating Kinase 4 (MARK4) Inhibition.
    Naz F; Shahbaaz M; Bisetty K; Islam A; Ahmad F; Hassan MI
    OMICS; 2015 Nov; 19(11):700-11. PubMed ID: 26565604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and evaluation of bioactive natural products as potential inhibitors of human microtubule affinity-regulating kinase 4 (MARK4).
    Mohammad T; Khan FI; Lobb KA; Islam A; Ahmad F; Hassan MI
    J Biomol Struct Dyn; 2019 Apr; 37(7):1813-1829. PubMed ID: 29683402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosmarinic Acid Exhibits Anticancer Effects via MARK4 Inhibition.
    Anwar S; Shamsi A; Shahbaaz M; Queen A; Khan P; Hasan GM; Islam A; Alajmi MF; Hussain A; Ahmad F; Hassan MI
    Sci Rep; 2020 Jun; 10(1):10300. PubMed ID: 32587267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of molecular mechanism of recognition between citral and MARK4: A newer therapeutic approach to attenuate cancer cell progression.
    Naz F; Khan FI; Mohammad T; Khan P; Manzoor S; Hasan GM; Lobb KA; Luqman S; Islam A; Ahmad F; Hassan MI
    Int J Biol Macromol; 2018 Feb; 107(Pt B):2580-2589. PubMed ID: 29079437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elucidation of Dietary Polyphenolics as Potential Inhibitor of Microtubule Affinity Regulating Kinase 4: In silico and In vitro Studies.
    Khan P; Rahman S; Queen A; Manzoor S; Naz F; Hasan GM; Luqman S; Kim J; Islam A; Ahmad F; Hassan MI
    Sci Rep; 2017 Aug; 7(1):9470. PubMed ID: 28842631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of α-Mangostin as a Potential Inhibitor of Microtubule Affinity Regulating Kinase 4.
    Khan P; Queen A; Mohammad T; Smita ; Khan NS; Hafeez ZB; Hassan MI; Ali S
    J Nat Prod; 2019 Aug; 82(8):2252-2261. PubMed ID: 31343173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, Structural Modification, and Bioactivity Evaluation of Substituted Acridones as Potent Microtubule Affinity-Regulating Kinase 4 Inhibitors.
    Voura M; Anwar S; Sigala I; Parasidou E; Fragoulidou S; Hassan MI; Sarli V
    ACS Pharmacol Transl Sci; 2023 Jul; 6(7):1052-1074. PubMed ID: 37470016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PKR-inhibitor binds efficiently with human microtubule affinity-regulating kinase 4.
    Naz F; Shahbaaz M; Khan S; Bisetty K; Islam A; Ahmad F; Hassan MI
    J Mol Graph Model; 2015 Nov; 62():245-252. PubMed ID: 26519933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based investigation of MARK4 inhibitory potential of Naringenin for therapeutic management of cancer and neurodegenerative diseases.
    Anwar S; Khan S; Shamsi A; Anjum F; Shafie A; Islam A; Ahmad F; Hassan MI
    J Cell Biochem; 2021 Oct; 122(10):1445-1459. PubMed ID: 34121218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acridone-pyrimidine hybrids- design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies.
    Murahari M; Prakash KV; Peters GJ; Mayur YC
    Eur J Med Chem; 2017 Oct; 139():961-981. PubMed ID: 28886509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Oncogenic Kinases: An In Vitro Validated Computational Approach Identified Potential Multi-Target Anticancer Compounds.
    Ikram N; Mirza MU; Vanmeert M; Froeyen M; Salo-Ahen OMH; Tahir M; Qazi A; Ahmad S
    Biomolecules; 2019 Mar; 9(4):. PubMed ID: 30925835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting tyrosine kinase: Development of acridone - pyrrole - oxindole hybrids against human breast cancer.
    Kaur M; Singh P
    Bioorg Med Chem Lett; 2019 Jan; 29(1):32-35. PubMed ID: 30446310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of quinazolinone tagged acridones as cytotoxic agents and their effects on EGFR tyrosine kinase.
    Babu YR; Bhagavanraju M; Reddy GD; Peters GJ; Prasad VV
    Arch Pharm (Weinheim); 2014 Sep; 347(9):624-34. PubMed ID: 24866341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myricetin inhibits breast and lung cancer cells proliferation via inhibiting MARK4.
    Anwar S; Khan S; Anjum F; Shamsi A; Khan P; Fatima H; Shafie A; Islam A; Hassan MI
    J Cell Biochem; 2022 Feb; 123(2):359-374. PubMed ID: 34751461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.